In a significant discussion revolving around advanced pharmaceutical industries, His Excellency Saeed Mubarak Al Hajeri, Minister of State and Chairman of the UAE Foundation, met with Dr. Noubar Afeyan, Founder and CEO of Flagship Pioneering and co-founder and Chairman of the renowned American biotechnology company, Moderna. The meeting focused on exploring investment opportunities and collaborative efforts in the pharmaceutical sector, aiming to strengthen ties between the UAE and the United States.
Strategic Partnership and Areas of Collaboration
The dialogue is part of the UAE’s strategic partnership with the United States, demonstrating a commitment to broaden cooperation with the private sector and global enterprises in priority fields. Key topics included research and development, knowledge transfer, and the cultivation of local pharmaceutical manufacturing capabilities. The discussion also highlighted the necessity of supporting research and clinical trials, contributing to an expanded base of scientific and industrial activities with added value.
Leveraging Expertise and Competitive Advantages
Both parties deliberated on opportunities to forge partnerships that synergise Moderna’s scientific and technological capabilities with the competitive advantages provided by the UAE’s business environment. This collaboration aims to attract quality investments that would foster growth in the pharmaceutical sector and contribute to the development of advanced therapeutic solutions.
Support for National Capacity Development
Al Hajeri underscored that the UAE offers comprehensive resources for the growth and expansion of global pharmaceutical companies. With advanced infrastructure, supportive regulatory frameworks, and attractive investment incentives, the UAE enhances its appeal for knowledge-based and high-tech projects. He also noted that developing national capabilities is a critical pillar in advancing the country’s pharmaceutical ecosystem, emphasising the importance of international partnerships to build sustainable expertise and broaden the national talent pool.